niacinamide has been researched along with Graft-Versus-Host Disease in 13 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Thirty-six patients with hematologic malignancies underwent transplantation at 11 sites." | 2.90 | Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide. ( Blackwell, B; Boelens, JJ; Cilloni, D; Frassoni, F; Freedman, LS; Hanna, R; Horwitz, ME; Hwang, WYK; Jagasia, M; Koh, LP; Kuball, J; Kurtzberg, J; Majhail, NS; Montesinos, P; Nierkens, S; Sanz, G; Stiff, PJ; Valcarcel, D; Wagner, JE; Wease, S, 2019) |
| "Sorafenib is a tyrosine kinase inhibitor, which inhibits the FLT3 tyrosine kinase and has shown encouraging activity in FLT3-ITD AML." | 2.79 | Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia. ( Antin, JH; Ballen, K; Chen, YB; Connolly, C; Curtis, M; Cutler, C; Del Rio, C; Dey, BR; El-Jawahri, A; Fathi, AT; Ho, VT; Joyce, A; Lane, AA; Levis, M; Li, S; McAfee, S; Rajkhowa, T; Rudek, M; Soiffer, R; Spitzer, TR; Valles, B; Verselis, S, 2014) |
| "Metastatic renal cell carcinoma (RCC) has a poor overall survival." | 2.44 | Treatment options for metastatic renal cell carcinoma: a review. ( Athar, U; Gentile, TC, 2008) |
| "Sorafenib treatment after HSCT appears to be feasible and highly effective with dose individualization according to patient tolerability." | 1.46 | Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia. ( Ahmed, SO; Aljurf, M; Antar, A; Battipaglia, G; Bazarbachi, A; Belhocine, R; Brissot, E; Dulery, R; Eder, S; El Cheikh, J; Giannotti, F; Isnard, F; Jestin, M; Lapusan, S; Legrand, O; Massoud, R; Mohty, M; Rasheed, W; Rubio, MT; Ruggeri, A; Shaheen, M; Vekhoff, A, 2017) |
| "Sorafenib treatment protocols included sorafenib in combination with chemotherapy inducing remission, and sorafenib monotherapy as mauntenance treatment after complete remission (CR)." | 1.43 | [Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation]. ( Fan, Z; Gao, Y; Huang, F; Jiang, Q; Liu, Q; Sun, J; Xu, N; Xuan, L; Zhang, Y, 2016) |
| "Sorafenib was administered either as prophylaxis in patients considered at very high risk for relapse (n = 6) or at the time of disease recurrence (n = 9)." | 1.42 | Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia. ( Adlard, K; Chang, B; Cooper, T; Estey, E; Garee, A; Gross, T; Gupta, S; Ho, PA; McGoldrick, S; Meshinchi, S; Neudorf, S; Pollard, JA; Sisler, I; Tarlock, K; Templeman, T; Thomson, B; Watt, T; Woolfrey, A, 2015) |
| " In 5 patients with pronounced toxicity, we switched to an alternating dosing schedule with 1 month on/1 month off sorafenib." | 1.42 | Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation. ( Gerull, S; Halter, JP; Heim, D; Medinger, M; Passweg, JR; Tschan-Plessl, A, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (7.69) | 29.6817 |
| 2010's | 10 (76.92) | 24.3611 |
| 2020's | 2 (15.38) | 2.80 |
| Authors | Studies |
|---|---|
| Saiyin, T | 3 |
| Kirkham, AM | 3 |
| Bailey, AJM | 3 |
| Shorr, R | 3 |
| Pineault, N | 3 |
| Maganti, HB | 3 |
| Allan, DS | 3 |
| de Koning, C | 1 |
| Tao, W | 1 |
| Lacna, A | 1 |
| van Veghel, K | 1 |
| Horwitz, ME | 2 |
| Sanz, G | 2 |
| Jagasia, MH | 1 |
| Wagner, JE | 2 |
| Stiff, PJ | 2 |
| Hanna, R | 2 |
| Cilloni, D | 2 |
| Valcárcel, D | 2 |
| Peled, T | 1 |
| Galamidi Cohen, E | 1 |
| Goshen, U | 1 |
| Pandit, A | 1 |
| Lindemans, CA | 1 |
| Jan Boelens, J | 1 |
| Nierkens, S | 2 |
| Battipaglia, G | 1 |
| Ruggeri, A | 1 |
| Massoud, R | 1 |
| El Cheikh, J | 1 |
| Jestin, M | 1 |
| Antar, A | 1 |
| Ahmed, SO | 1 |
| Rasheed, W | 1 |
| Shaheen, M | 1 |
| Belhocine, R | 1 |
| Brissot, E | 1 |
| Dulery, R | 1 |
| Eder, S | 1 |
| Giannotti, F | 1 |
| Isnard, F | 1 |
| Lapusan, S | 1 |
| Rubio, MT | 1 |
| Vekhoff, A | 1 |
| Aljurf, M | 1 |
| Legrand, O | 1 |
| Mohty, M | 1 |
| Bazarbachi, A | 1 |
| Wease, S | 1 |
| Blackwell, B | 1 |
| Frassoni, F | 1 |
| Boelens, JJ | 1 |
| Jagasia, M | 1 |
| Kuball, J | 1 |
| Koh, LP | 1 |
| Majhail, NS | 1 |
| Hwang, WYK | 1 |
| Kurtzberg, J | 1 |
| Freedman, LS | 1 |
| Montesinos, P | 1 |
| Chen, YB | 1 |
| Li, S | 1 |
| Lane, AA | 1 |
| Connolly, C | 1 |
| Del Rio, C | 1 |
| Valles, B | 1 |
| Curtis, M | 1 |
| Ballen, K | 1 |
| Cutler, C | 1 |
| Dey, BR | 1 |
| El-Jawahri, A | 1 |
| Fathi, AT | 1 |
| Ho, VT | 1 |
| Joyce, A | 1 |
| McAfee, S | 1 |
| Rudek, M | 1 |
| Rajkhowa, T | 1 |
| Verselis, S | 1 |
| Antin, JH | 1 |
| Spitzer, TR | 1 |
| Levis, M | 1 |
| Soiffer, R | 1 |
| Tarlock, K | 1 |
| Chang, B | 1 |
| Cooper, T | 1 |
| Gross, T | 1 |
| Gupta, S | 1 |
| Neudorf, S | 1 |
| Adlard, K | 1 |
| Ho, PA | 1 |
| McGoldrick, S | 1 |
| Watt, T | 1 |
| Templeman, T | 1 |
| Sisler, I | 1 |
| Garee, A | 1 |
| Thomson, B | 1 |
| Woolfrey, A | 1 |
| Estey, E | 1 |
| Meshinchi, S | 1 |
| Pollard, JA | 1 |
| Tschan-Plessl, A | 1 |
| Halter, JP | 1 |
| Heim, D | 1 |
| Medinger, M | 1 |
| Passweg, JR | 1 |
| Gerull, S | 1 |
| Gu, B | 1 |
| Chen, GH | 1 |
| Shen, HJ | 1 |
| Ma, X | 1 |
| Fu, CC | 1 |
| Han, Y | 1 |
| Tang, XW | 1 |
| Miao, M | 1 |
| Qiu, HY | 1 |
| Sun, AN | 1 |
| Wu, DP | 1 |
| Zhang, Y | 1 |
| Xuan, L | 1 |
| Fan, Z | 1 |
| Huang, F | 1 |
| Jiang, Q | 1 |
| Xu, N | 1 |
| Gao, Y | 1 |
| Sun, J | 1 |
| Liu, Q | 1 |
| Winkler, J | 1 |
| Rech, D | 1 |
| Kallert, S | 1 |
| Rech, J | 1 |
| Meidenbauer, N | 1 |
| Roesler, W | 1 |
| Mackensen, A | 1 |
| Yokoyama, H | 1 |
| Lundqvist, A | 1 |
| Su, S | 1 |
| Childs, R | 1 |
| Sorà, F | 1 |
| Chiusolo, P | 1 |
| Metafuni, E | 1 |
| Bellesi, S | 1 |
| Giammarco, S | 1 |
| Laurenti, L | 1 |
| Ausoni, G | 1 |
| Zini, G | 1 |
| Bayer, AJ | 1 |
| Mario, B | 1 |
| Leone, G | 1 |
| Sica, S | 1 |
| Athar, U | 1 |
| Gentile, TC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies[NCT01816230] | Phase 1/Phase 2 | 36 participants (Actual) | Interventional | 2013-04-30 | Completed | ||
| Phase I Trial of Sorafenib Maintenance Therapy for Patients With FLT3-ITD AML After Allogeneic Stem Cell Transplantation[NCT01398501] | Phase 1 | 22 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Assess the cumulative incidence of patients with NiCord®-derived neutrophil engraftment at 42 days following transplantation. (NCT01816230)
Timeframe: 42 days
| Intervention | percentage of patients (Number) |
|---|---|
| NiCord® | 94 |
2 reviews available for niacinamide and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Clinical Outcomes of Umbilical Cord Blood Transplantation Using Ex Vivo Expansion: A Systematic Review and Meta-Analysis of Controlled Studies.
Topics: Coculture Techniques; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft vs Host Disease; Hema | 2023 |
Clinical Outcomes of Umbilical Cord Blood Transplantation Using Ex Vivo Expansion: A Systematic Review and Meta-Analysis of Controlled Studies.
Topics: Coculture Techniques; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft vs Host Disease; Hema | 2023 |
Clinical Outcomes of Umbilical Cord Blood Transplantation Using Ex Vivo Expansion: A Systematic Review and Meta-Analysis of Controlled Studies.
Topics: Coculture Techniques; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft vs Host Disease; Hema | 2023 |
Clinical Outcomes of Umbilical Cord Blood Transplantation Using Ex Vivo Expansion: A Systematic Review and Meta-Analysis of Controlled Studies.
Topics: Coculture Techniques; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft vs Host Disease; Hema | 2023 |
Clinical Outcomes of Umbilical Cord Blood Transplantation Using Ex Vivo Expansion: A Systematic Review and Meta-Analysis of Controlled Studies.
Topics: Coculture Techniques; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft vs Host Disease; Hema | 2023 |
Clinical Outcomes of Umbilical Cord Blood Transplantation Using Ex Vivo Expansion: A Systematic Review and Meta-Analysis of Controlled Studies.
Topics: Coculture Techniques; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft vs Host Disease; Hema | 2023 |
Clinical Outcomes of Umbilical Cord Blood Transplantation Using Ex Vivo Expansion: A Systematic Review and Meta-Analysis of Controlled Studies.
Topics: Coculture Techniques; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft vs Host Disease; Hema | 2023 |
Clinical Outcomes of Umbilical Cord Blood Transplantation Using Ex Vivo Expansion: A Systematic Review and Meta-Analysis of Controlled Studies.
Topics: Coculture Techniques; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft vs Host Disease; Hema | 2023 |
Clinical Outcomes of Umbilical Cord Blood Transplantation Using Ex Vivo Expansion: A Systematic Review and Meta-Analysis of Controlled Studies.
Topics: Coculture Techniques; Cord Blood Stem Cell Transplantation; Fetal Blood; Graft vs Host Disease; Hema | 2023 |
Treatment options for metastatic renal cell carcinoma: a review.
Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic A | 2008 |
3 trials available for niacinamide and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Lymphoid and myeloid immune cell reconstitution after nicotinamide-expanded cord blood transplantation.
Topics: Adolescent; Adult; Cord Blood Stem Cell Transplantation; Graft vs Host Disease; Hematopoietic Stem C | 2021 |
Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.
Topics: Adolescent; Adult; Cord Blood Stem Cell Transplantation; Disease-Free Survival; Female; Fetal Blood; | 2019 |
Phase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.
Topics: Adult; Aged; Allografts; Disease-Free Survival; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Di | 2014 |
8 other studies available for niacinamide and Graft-Versus-Host Disease
| Article | Year |
|---|---|
Efficacy and feasibility of sorafenib as a maintenance agent after allogeneic hematopoietic stem cell transplantation for Fms-like tyrosine kinase 3-mutated acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Chemotherapy, Adjuvant; Disease-Free Survival; Feasibility | 2017 |
Sorafenib treatment following hematopoietic stem cell transplant in pediatric FLT3/ITD acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; | 2015 |
Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allogeneic transplantation.
Topics: Adult; Aged; Female; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hematopoietic Stem Cell Tran | 2015 |
[Improved clinical outcome of acute myeloid leukemia with FLT3-ITD mutation treated with sorafenib].
Topics: Antineoplastic Agents; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hem | 2016 |
[Sorafenib as salvage therapy in refractory relapsed acute myeloid leukemia with positive FLT3 mutation].
Topics: Antineoplastic Agents; Disease-Free Survival; fms-Like Tyrosine Kinase 3; Graft vs Host Disease; Hem | 2016 |
Sorafenib induces sustained molecular remission in FLT3-ITD positive AML with relapse after second allogeneic stem cell transplantation without exacerbation of acute GVHD: a case report.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Female; fms-Like Tyrosine Kinase 3; Graft vs Host D | 2010 |
Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation.
Topics: Animals; Antineoplastic Agents; Benzenesulfonates; Carcinoma, Renal Cell; Cell Line, Tumor; Graft vs | 2010 |
Sorafenib for refractory FMS-like tyrosine kinase receptor-3 (FLT3/ITD+) acute myeloid leukemia after allogenic stem cell transplantation.
Topics: Adult; Antineoplastic Agents; Benzenesulfonates; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase | 2011 |